Drug Search Results
More Filters [+]

Pergolide

Alternative Names: pergolide, permax
Latest Update: 2022-10-10
Latest Update Note: News Article

Product Description

Pergolide is an oral dopamine receptor agonist used predominantly in the therapy of Parkinson disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pergolide)

Mechanisms of Action: D2 Agonist,D3 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Canada | Chile | Colombia | Egypt | Germany | Hong Kong | India | Ireland | Italy | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Slovenia | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pergolide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events